Eli Lilly in pact with Magnet Bio to develop cancer drugs in a deal worth up to $1.25B
by
Contributor since / Followers
Contributor since / Followers
1 month ago
jetcityimage/iStock Editorial via Getty Images
Magnet Biomedicine announced Friday it has reached a licensing agreement worth up to $1.25B with Eli Lilly (NYSE:LLY) to develop cancer drugs leveraging the company’s TrueGlue discovery platform.
As part of the deal, Boston, the Massachusetts-based firm will receive up to $40M in